Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

NCT05952596 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine

NCT06817187 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02853929 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults

NCT00311493 ·Status: COMPLETED ·Phase: PHASE4

Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines

NCT05193734 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants

NCT00303316 ·Status: COMPLETED ·Phase: PHASE3

Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults

NCT00387634 ·Status: COMPLETED ·Phase: PHASE4

First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine

NCT01188512 ·Status: COMPLETED ·Phase: PHASE1

Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

NCT00289796 ·Status: COMPLETED ·Phase: PHASE2

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666 ·Status: COMPLETED ·Phase: PHASE2

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

NCT01277705 ·Status: COMPLETED ·Phase: PHASE3

GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region

NCT04494581 ·Status: COMPLETED

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

NCT00317109 ·Status: COMPLETED ·Phase: PHASE3

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

NCT00291343 ·Status: COMPLETED ·Phase: PHASE3

Pertussis Vaccination in Pregnant Women

NCT03909126 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers

NCT04535037 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

NCT04648241 ·Status: COMPLETED ·Phase: PHASE3

Viaskin Pertussis Vaccine Trial

NCT03035370 ·Status: COMPLETED ·Phase: PHASE1

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

NCT02408926 ·Status: COMPLETED ·Phase: PHASE4

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

NCT00595309 ·Status: COMPLETED ·Phase: PHASE3

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

NCT00831311 ·Status: COMPLETED ·Phase: PHASE2

Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

NCT02360514 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

NCT00348881 ·Status: COMPLETED ·Phase: PHASE3

Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

NCT00412516 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years

NCT00452621 ·Status: COMPLETED ·Phase: PHASE4